|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||29.88 - 29.88|
|52-week range||29.88 - 29.88|
|Beta (5Y monthly)||1.58|
|PE ratio (TTM)||45.86|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.
Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.
Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.